Document:

Stockholder Agreement with Bristol-Meyers Squibb Company

 
EXHIBIT 4.5.1

 
STOCKHOLDER AGREEMENT 
 
THIS STOCKHOLDER AGREEMENT (this
“Agreement”), effective as of February 28, 2003 (the “Effective Date”), is entered into between DELTAGEN, INC., a Delaware corporation with a place of business at 740 Bay Road, Redwood City, CA 94063
(“Deltagen”) and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation with a place of business at Route 206 and Province Line Road, Princeton, NJ 08543 (“BMS”). Deltagen and BMS are sometimes referred to
herein individually, as a “Party” and collectively, as the “Parties.” 
 
WHEREAS, XenoPharm, Inc. (“XenoPharm”), a wholly owned subsidiary of Deltagen licensed certain patents, patent applications, know how and materials from the Salk Institute for
Biological Studies, the Baylor College of Medicine and the University of Sydney; 
 
WHEREAS, BMS wishes to obtain, and XenoPharm wishes to grant to BMS, a license of certain rights under the XenoPharm patent rights and the XenoPharm know how; 
 
WHEREAS, pursuant to that certain license agreement
effective as of the date hereof among XenoPharm, Deltagen and BMS (the “License Agreement”) Deltagen and XenoPharm have granted the license that BMS wishes to obtain under certain XenoPharm patent rights and XenoPharm know how; and

 
WHEREAS, in consideration of and as a
condition precedent to entering into the License Agreement, Deltagen wishes to obtain certain monetary and contractual rights from BMS as provided herein; 
 
NOW, THEREFORE, in consideration of the promises and the mutual covenants and conditions set forth in
this Agreement and in the License Agreement, the Parties agree as follows: 
 
1.    CONSIDERATION; TERMINATION OF REGISTRATION RIGHTS AGREEMENT. 
 
1.1    Consideration.    As consideration for the rights granted by XenoPharm and Deltagen
under the License Agreement, BMS shall pay to Deltagen on the Effective Date an amount in cash which is equal to the closing price on the New York Stock Exchange of Deltagen common stock on the Effective Date multiplied by 1.8 million, which
represents fair and adequate consideration for the rights granted to BMS under the License Agreement. BMS shall have the right to use Deltagen common stock to satisfy the amount due under this Section 1.1. In the event BMS elects to use
Deltagen common stock to satisfy the amount due under this Section 1.1, BMS shall sell, transfer, assign and deliver to Deltagen, on the Effective Date, One Million Eight Hundred Thousand (1,800,000) shares of common stock, par value $0.001
per share, of Deltagen, that are currently held by BMS (the “BMS Shares”). In furtherance of the foregoing, BMS shall deliver to Deltagen, on the Effective Date, certificates representing the BMS Shares, free and clear of any
claims, liens or encumbrances of any nature whatsoever, duly endorsed in blank for transfer or accompanied by stock powers duly executed in blank. 

 
1.2    Registration Rights Agreement.    Notwithstanding anything to the contrary in any agreement between BMS and Deltagen, BMS hereby irrevocably waives and shall have no further
rights, preferences or privileges arising by contract and relating to any shares of capital stock of Deltagen held by BMS, beyond the rights associated with or attached to the Deltagen common stock pursuant to Deltagen’s Certificate of
Incorporation, except as set forth in this Section 1.2. Without limiting the generality of the foregoing, it is expressly acknowledged that, except as set forth in this Section 1.2, BMS shall have no further rights and Deltagen shall
have no further obligations relating to shares of Deltagen common stock arising under that certain Purchase Agreement dated as of February 8, 2002 between BMS and Deltagen, or under that certain Registration Rights Agreement dated as of February 16,
2002, as amended on May 9, 2002, between BMS and Deltagen. As of the date hereof, to the best of Deltagen’s knowledge, BMS is not an affiliate of Deltagen within the meaning of Rule 144 of the Securities Act of 1934, as amended, and BMS
otherwise is entitled to the same rights with respect to the Deltagen common stock it holds, that inure generally to the shares of Deltagen’s common stock under its Certificate of Incorporation. Deltagen shall not make any filings with the SEC
seeking to cause its Registration Statement (Registration No. 333-88364) to cease to be effective prior to February 16, 2004 and will use commercially reasonable efforts to maintain that Registration Statement until February 16, 2004. 
 
2.    REPRESENTATIONS AND WARRANTIES. 
 
2.1    Mutual Representations and
Warranties.    Each Party hereby represents and warrants to the other Parties as follows: 
 
2.1.1    Such Party is a corporation duly organized, validly existing and in good standing under the
laws of the jurisdiction in which it is incorporated. 
 
2.1.2    Such Party (a) has the requisite power and authority to enter into this Agreement and to perform its obligations hereunder, and (b) has taken all corporate action necessary on its part to
authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable
against such Party in accordance with its terms. 
 
2.1.3    All necessary consents, approvals and authorizations of all governmental authorities and other Persons required to be obtained by such Party in connection with its execution of this Agreement
have been obtained, other than such consents, approvals and authorizations which, if not obtained, would not have a material adverse effect on the performance by such Party of its material obligations under this Agreement. 
 
2.1.4    The execution
and delivery of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable laws or regulations, and (b) do not conflict with, or constitute a default under, any
contractual obligation of such Party, except, in either case, where such conflicts, violations or defaults would not have a material adverse effect on the performance by such Party of its material obligations under this Agreement. 

 
2.2    BMS Representations and Warranties.    BMS hereby represents and warrants to Deltagen and XenoPharm that BMS is the owner of the BMS Shares, free and clear of any claims, liens or
encumbrances of any nature whatsoever. 
 
3.    INDEMNIFICATION; AND CERTAIN OTHER PROVISIONS. 
 
3.1    BMS Indemnity.    BMS shall indemnify and hold Deltagen, its respective Affiliates and each of their respective officers, directors, employees,
consultants and agents harmless from and against all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) resulting from all claims, demands, actions and other proceedings to the extent arising from (a) a
material breach of any representation, warranty or covenant of BMS under this Agreement, or (b) the negligence or willful misconduct of BMS or any of its Affiliates or any of their respective employees, consultants or agents in the performance of
its and/or any of their obligations, and its and/or any of their permitted activities, under this Agreement, except, but only to the extent that, with respect to each of the foregoing subsections (a) through (b), any such claim, demand, action or
other proceeding arises from any breach of any representation, warranty or covenant by Deltagen or from the negligence or willful misconduct of Deltagen. 
 
3.2    Deltagen Indemnity.    Deltagen shall indemnify and hold BMS and its Affiliates and
each of their respective officers, directors, employees, consultants and agents harmless from and against all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) resulting from all claims, demands, actions
and other proceedings to the extent arising from (a) a material breach of any representation, warranty or covenant of Deltagen under this Agreement, or (b) the negligence or willful misconduct of Deltagen in the performance of its obligations to be
performed under this Agreement; except, but only to the extent that, with respect to each of the foregoing subsections (a) and (b), any such claim, demand, action or other proceeding arises from any breach of any representation, warranty or covenant
by BMS or from the negligence or willful misconduct of BMS. 
 
3.3    Indemnification Procedures.    A Party (the “Indemnitee”) that intends to claim indemnification under this Article 3 shall promptly notify the other Party (the
“Indemnitor”) of any claim, demand, action or other proceeding for which the Indemnitee intends to claim such indemnification. The Indemnitor shall have the right to participate, in and to the extent the Indemnitor so desires,
jointly with any other indemnitor similarly noticed, to assume the defense thereof with counsel selected by the Indemnitor; provided, however, that if representation of the Indemnitee by such counsel first selected by the Indemnitor
would be inappropriate due to a conflict of interest between such Indemnitee and any other party represented by such counsel, then the Indemnitor shall select other counsel for the defense of Indemnitee, with the fees and expenses to be paid by the
Indemnitor, such other counsel to be approved by the Indemnitee and such approval not to be unreasonably withheld. The indemnity obligations under this Article 3 shall not apply to amounts paid in settlement of any claim, demand, action or
other proceeding if such settlement is effected without the prior express written consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed. The failure to deliver notice to the Indemnitor within a reasonable time after
notice of any such claim or demand, or the commencement of any such action or other proceeding, if prejudicial to its ability to defend such claim, demand, action or other proceeding, shall relieve such Indemnitor of any liability to the 

Indemnitee under this Article 3 with respect thereto, but the omission so to deliver notice to the Indemnitor shall not relieve it of
any liability that it may have to the Indemnitee otherwise than under this Article 3. The Indemnitor may not settle or otherwise consent to an adverse judgment in any such claim, demand, action or other proceeding, that diminishes the rights
or interests of the Indemnitee without the prior express written consent of the Indemnitee, which consent shall not be unreasonably withheld or delayed. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its
legal representatives in the investigation of any claim, demand, action or other proceeding covered by this Article 3. 
 
3.4    DISCLAIMER.    IN NO EVENT SHALL ANY PARTY BE LIABLE TO ANY OTHER PARTY FOR
CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING ANY LOSS OF PROFITS, SAVINGS OR REVENUE, OR THE CLAIMS OF THIRD PARTIES, WHETHER OR NOT ADVISED OF THE POSSIBILITY OF SUCH LIABILITY OR LOSS, HOWSOEVER CAUSED,
AND ON ANY THEORY OF LIABILITY, RELATING TO OR IN CONNECTION WITH THIS AGREEMENT. 
 
3.5    Affiliates.    For purposes of this Article 3, “Affiliate” shall mean, with respect to a Party to this Agreement, any Person
directly or indirectly controlling or controlled by or under common control with such party, where “control” in this context is defined as the ownership of or the ability to control, directly or indirectly, more than fifty percent (50%) of
the voting stock or other voting interests in the Person in question. In the event that BMS acquires control of Lexicon, Genetics Inc., Lexicon Genetics, Inc. shall not be considered an Affiliate for the purposes of this Agreement. 
 
4.    MISCELLANEOUS. 
 
4.1    Governmental Consents and
Approvals; Compliance with Law.    Each Party shall be responsible, at its own expense, for complying with all applicable laws and obtaining all applicable governmental and regulatory approvals, consents, permits and licenses
to perform its duties and responsibilities under this Agreement. 
 
4.2    Notices.    Any consent, notice or report required or permitted to be given or made under this Agreement by one of the Parties to any other Party shall be in writing and shall be
delivered in person or by DHL, Federal Express (or other courier service requiring signature upon receipt) or sent by air mail, postage prepaid, or facsimile (confirmed by a telephone conversation with the recipient) to the addresses set forth below
(or to such other address as the addressee shall have last furnished in writing to the addressor). Notices shall be effective upon receipt by the addressee. 
 

	 	    	 If to Deltagen:
	  	 Deltagen, Inc.
 740 Bay Road
 Redwood City, CA 94063
 Attention: President
 cc: General Counsel, at the same address
 Telephone: (650) 569 5100
 Facsimile: (650)
569 5280
	 	 

 

	 	    	 If to BMS:
	  	 Bristol-Myers Squibb Company
 Route 206 and Province Line Road
 Princeton, NJ 08543
 Attention: Charles Linzner
 Facsimile No.: 609 252 4232
 Telephone No.: 609 252 4311
	 	 

 
4.3    Applicable Law.    This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law principles
thereof. 
 
4.4    Entire
Agreement; Amendment.    This Agreement, together with the License Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. All express or implied representations, agreements and
understandings, either oral or written, heretofore made are expressly superseded by this Agreement and the License Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by all of the
Parties hereto. 
 
4.5    Headings; Interpretation.    The captions to the several Articles and Sections hereof are not a part of this Agreement, but are merely guides or labels to assist in locating and
reading the several Articles and Sections hereof. In this Agreement, the singular shall include the plural and vice versa and the word “including” shall be deemed to be followed by the phrase “without limitation.” This Agreement
has been prepared jointly and no rule of strict construction shall be applied against any Party. 
 
4.6    Independent Contractors.    Each Party hereby acknowledges that the Parties shall be independent contractors and that the relationship between the
Parties shall not constitute a partnership, joint venture or agency. No Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on any other Party, without the
prior consent of such other Party to do so. 
 
4.7    Waiver.    The waiver by a Party of any right hereunder, or of any failure to perform or breach by any other Party hereunder, shall not be deemed a waiver of any other right
hereunder or of any other breach or failure by such other Party hereunder whether of a similar nature or otherwise. 
 
4.8    Other Activities.    Except as otherwise expressly provided in this Agreement,
nothing in this Agreement shall preclude any Party from conducting other programs (either for its own benefit or with or for the benefit of any other Person) to conduct research, or to develop or commercialize products or services, for use in any
field. 
 
4.9    Severability.    If any provision of this Agreement, or the application thereof to any person, entity, place or circumstance, shall be held by a court of competent jurisdiction to
be invalid, unenforceable or void, the remainder of this Agreement and such provisions as applied to other persons, entities, places and circumstances shall remain in full force and effect only if, after excluding the portion deemed to be
unenforceable, the remaining terms shall provide for the consummation of the transactions contemplated hereby in substantially the same manner as 

originally set forth herein. In such event, the Parties shall negotiate, in good faith, a substitute, valid and enforceable provision or
agreement that most nearly effects the Parties’ intent in entering into this Agreement. 
 
4.10    Counterparts.    This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
 
IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above. 
 

	 DELTAGEN, INC.

	
	 By:
	 	 /S/    MARK
MOORE        

	 Name:
	 	 Mark Moore

	 Title:
	 	 Chief Scientific Officer

	
	 BRISTOL-MYERS SQUIBB COMPANY

	
	 By:
	 	 /S/    SANDRA
LEUNG        

	 Name:
	 	 Sandra Leung

	 Title:
	 	 Vice President & Secretary<PAGE>

                                                                 Exhibit 10.64.1

                        CONFIDENTIAL TREATMENT REQUESTED.
CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST
FOR CONFIDENTIAL TREATMENT AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION.

                              SETTLEMENT AGREEMENT

        This SETTLEMENT AGREEMENT ("Agreement") is made and entered into as of
September 19, 2001 ("Effective Date"), by and among Lexicon Genetics
Incorporated ("Lexicon"), a corporation organized under the laws of the State of
Delaware, having its principal place of business in The Woodlands, Texas,
GenPharm International, Inc. ("GenPharm"), a California corporation having a
principal place of business in Milpitas, California, The University of Utah
Research Foundation ("Foundation"), having a principal place of business at Salt
Lake City, Utah, and Deltagen, Inc. ("Deltagen"), a corporation organized under
the laws of the State of Delaware, having its principal place of business in
Menlo Park, California.

                                    RECITALS

        Lexicon is an exclusive licensee in certain fields with the right to
bring suit on U.S. Patent Nos. 5,789,215 (the "'215 patent"), 5,627,059,
5,487,992, 5,631,153; 5,464,764 and 6,204,061 (the "Capecchi patents") (the '215
patent and Capecchi patents are referred to collectively as the "Patents").

        On May 24, 2000, Lexicon filed a complaint in the United States District
Court for the District of Delaware, Case No. 00-516-JFF, in which GenPharm, the
assignee of the '215 patent, was subsequently joined as a co plaintiff (the
"Delaware Action"), seeking judgment that Deltagen infringed the '215 patent and
an award of damages and injunctive relief against Deltagen. On July 19, 2001,
Lexicon and the Foundation filed an amended complaint in the United States
District Court for the Northern District of California, Case No. CVOO-21060-PVT
ADR (the "California Action") (the Delaware Action and the California Action are
referred to collectively as the "Actions"), seeking judgment that Deltagen
infringed the Capecchi Patents and an award of damages and injunctive relief
against Deltagen.

        On November 14, 2000, Deltagen filed patent invalidity and
noninfringement declaratory judgment counterclaims and antitrust counterclaims
against Lexicon and GenPharm in the Delaware Action. On April 23, 2001, Deltagen
filed a motion seeking to amend its counterclaims in the Delaware Action to add
additional federal and state unfair competition claims. Lexicon and GenPharm
opposed Deltagen's motion to amend, which is still pending. On August 15, 2001,
Deltagen filed patent invalidity and noninfringement declaratory judgment
counterclaims against Lexicon and the Foundation in the California Action.

        Concurrently with their execution of this Agreement, Lexicon and
Deltagen have entered into a Sublicense Agreement under which Lexicon has
granted Deltagen certain rights under the Patents (the "Sublicense Agreement"),
and a DeltaBase Collaboration Agreement under which Deltagen has granted Lexicon
certain rights to information and materials in its DeltaBase(TM) product and
related intellectual property (the "Collaboration Agreement").

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

<PAGE>

        Lexicon, Deltagen, GenPharm and the Foundation now wish to settle any
and all claims and disputes among them relating to the Actions and the Patents.

        NOW, THEREFORE, in consideration of the above premises and mutual
covenants hereinafter contained, Lexicon, Deltagen, GenPharm and the Foundation
agree as follows:

1.      DISMISSAL OF THE ACTION

        1.1     Within five (5) days of the Effective Date of this Agreement,
Lexicon, Deltagen, GenPharm and the Foundation shall file stipulated dismissals
with prejudice to dismiss the entirety of both Actions, including all claims and
counterclaims filed in the Actions, in the form attached hereto as Exhibit A.

        1.2     Lexicon, GenPharm and the Foundation, and each of them,
represent that, to the best of their knowledge, other than the claims and
counterclaims asserted in the Actions, no other presently asserted claims or
counterclaims against Deltagen exist as of the Effective Date of this Agreement,
and that none of Lexicon, GenPharm and the Foundation has assigned, or will
assign, any such claims or counterclaims against Deltagen to a third party as of
the Effective Date of this Agreement.

        1.3     Deltagen represents that, to the best of its knowledge, other
than the claims and counterclaims asserted in the Actions, no other presently
asserted claims or counterclaims against Lexicon, GenPharm or the Foundation
exist as of the Effective Date of this Agreement, and that Deltagen has not
assigned, and will not assign, any such claims or counterclaims against Lexicon,
GenPharm or the Foundation to a third party as of the Effective Date of this
Agreement.

        1.4     Lexicon, GenPharm and the Foundation, on the one hand, and
Deltagen, on the other hand, shall each bear their own costs and legal fees
associated with the Actions, and neither Lexicon, GenPharm or the Foundation, on
the one hand, nor Deltagen, on the other hand, shall file, or cause to be filed,
any action or proceeding against each other to recover any costs or legal fees
associated with the Actions. Nothing herein shall affect any contractual
obligations of Lexicon to GenPharm or the Foundation with respect to the payment
or reimbursement by Lexicon of costs and legal expenses incurred by GenPharm and
the Foundation in connection with the Actions.

2.      SETTLEMENT AGREEMENTS

        2.1     The Sublicense Agreement has been duly authorized, executed and
delivered by, and constitutes a valid and binding obligation of, each of Lexicon
and Deltagen, enforceable in accordance with its terms, except as enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium
or similar laws affecting creditors' and contracting parties' rights generally
and except as enforceability may be subject to general principles of equity
(regardless of whether such enforceability is considered in a proceeding in
equity or at law).

        2.2     The Collaboration Agreement has been duly authorized, executed
and delivered by, and constitutes a valid and binding obligation of, each of
Lexicon and Deltagen, enforceable

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                        2

<PAGE>

in accordance with its terms, except as enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting creditors' and contracting parties' rights generally and except as
enforceability may be subject to general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at law).

3.      RELEASES

        3.1     Lexicon, GenPharm and the Foundation release and discharge
Deltagen and its predecessors, successors, subsidiaries, divisions, affiliates,
officers, directors, agents and employees, from any and all claims,
counterclaims, cross claims, demands, causes of action, obligations and
liabilities of any kind, whether liquidated or unliquidated, whether at this
time suspected, known or unknown, and whether anticipated or unanticipated,
which Lexicon, GenPharm and the Foundation had in the past or had at any time up
to the Effective Date, or which are based on any acts or omissions occurring
prior to the Effective Date, against Deltagen that were asserted in or could
have been asserted in, and are related to or arise from the Patents or any other
allegations, claims and counterclaims alleged in the Actions, including without
limitation any compulsory counterclaims that should have been made in the
Actions. This release by Lexicon, GenPharm and the Foundation shall not affect
any warranty or contractual claims by Lexicon against Deltagen under the
Sublicense Agreement or Collaboration Agreement.

        3.2     Deltagen releases and discharges Lexicon, GenPharm and the
Foundation and their predecessors, successors, subsidiaries, divisions,
affiliates, officers, directors, agents and employees, from any and all claims,
counterclaims, cross claims, demands, causes of action, obligations and
liabilities of any kind, whether liquidated or unliquidated, whether at this
time suspected, known or unknown, and whether anticipated or unanticipated,
which Deltagen had in the past or had at any time up to the Effective Date, or
which are based on any acts or omissions occurring prior to the Effective Date,
against Lexicon, GenPharm and the Foundation that were asserted in or could have
been asserted in, and are related to or arise from the Patents or any other
allegations, claims and counterclaims alleged in the Actions, including without
limitation any compulsory counterclaims that should have been made in the
Actions. This release by Deltagen shall not affect any warranty or contractual
claims by Deltagen against Lexicon under the Sublicense Agreement or
Collaboration Agreement.

        3.3     The releases by the parties herein include an express, knowing
and voluntary waiver and relinquishment to the fullest extent permitted by law
of the provisions, rights and benefits of Section 1542 of the California Civil
Code (or any law of similar effect), which reads as follows:

                A GENERAL RELEASE DOES NOT EXTEND TO THE
                CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR
                SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF
                EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM
                MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT
                WITH THE DEBTOR.

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                        3

<PAGE>

4.      RETURN OF DOCUMENTS RELATING TO THE ACTION

        4.1     The parties agree to treat the documents and other materials
produced in connection with the Actions in accordance with the Stipulated
Protective Orders in these Actions.

5.      MISCELLANEOUS

        5.1     Entire Understanding. This Agreement sets forth the entire
understanding of the parties on the subject matter herein, and no amendment to
this Agreement shall be effective unless in writing signed by an authorized
representative of each party.

        5.2     No Admissions. This Agreement shall not in any way be construed
as an admission of fact or liability by Lexicon, Deltagen, GenPharm or the
Foundation that any of them has acted wrongfully with respect to the other or
any other person, or that any of them has any rights against the other or any of
the others' current or former officers, directors, employees or agents, or for
any other fact or purpose not specifically set forth herein. Lexicon, GenPharm
and the Foundation, on the one hand, and Deltagen, on the other, specifically
deny any liability for wrongful acts against one another.

        5.3     Confidentiality. The parties shall keep the terms and conditions
of this Agreement (except the existence of this Agreement) confidential and
shall not divulge the terms and conditions to any third party except: (i) with
the prior written consent of the other parties; (ii) to any governmental body
having jurisdiction to request such information; or (iii) as otherwise may be
required by law or legal process.

        5.4     Notices. All notices required or permitted to be given hereunder
shall be in writing and be deemed as given when dispatched, and shall be
addressed as follows and dispatched by registered or certified airmail in any
post office in the United States:

        If to Deltagen:        Deltagen, Inc.
                               740 Bay Road
                               Redwood City, CA 94063 2469
                               Attention: President

                               Copy to: General Counsel

        If to Lexicon:         Lexicon Genetics Incorporated
                               4000 Research Forest Drive
                               The Woodlands, Texas 77381
                               Attention: President

                               Copy to: Vice President, Intellectual Property

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                        4

<PAGE>

        If to GenPharm:        GenPharm International, Inc.
                               c/o Medarex, Inc.
                               707 State Road
                               Princeton, NJ 08540
                               Attention: President

                               Copy to: General Counsel

        If to the Foundation:  University of Utah
                               Department of Technology Transfer
                               615 Arapeen Drive
                               Suite 110
                               Salt Lake City, Utah 84108
                               Attention: Brent Brown

                               Copy to:
                               University of Utah General Counsel's Office
                               309 Park Building
                               Salt Lake City, Utah 84108

        5.5     Any party may at any time give written notice of a change of its
address to the other party.

        5.6     Assignment. No party may assign its right or delegate its
obligations under this Agreement without the prior written consent of the other
parties, except to the surviving entity in a merger or consolidation in which it
participates or to a successor of all or substantially all of the assigning
party's stock, assets or business to which this Agreement relates. Any
unauthorized assignment of this Agreement shall be void. Subject to the
foregoing, the rights and liabilities of the parties will bind and inure to the
benefit of their respective successors and assigns.

        5.7     Disputes. If any controversy or claim should arise under this
Agreement between Lexicon and Deltagen, the matter shall be referred to an
individual designated by the Chief Executive Officer (or the equivalent
position) of Lexicon and an individual designated by the Chief Executive Officer
(or the equivalent position) of Deltagen (the "Representatives"), who will
attempt in good faith to resolve such controversy or claim promptly by
negotiations. If the matter has not been resolved within [*] days of the first
meeting of the Representatives (which period may be extended by mutual
agreement) concerning such matter, such matter shall be resolved by binding
arbitration in accordance with this Section 5.7. Any and all claims, disputes or
controversies arising under, out of, or in connection with this Agreement that
are not resolved by the parties under this Section 5.7 shall be resolved by
final and binding arbitration in [*] under the Commercial Arbitration Rules of
the American Arbitration Association as then in effect. The arbitrators shall
have no power to add to, subtract from or modify any of the terms or conditions
of this Agreement or to award punitive damages. Judgment on an arbitral award
may be entered by any court of competent jurisdiction.

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                        5

<PAGE>

        5.8     Governing Law. This Agreement and the rights and obligations of
the parties under this Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, without giving effect to any
choice of law rule that would cause the application of the laws of any
jurisdiction other than the laws of the State of Delaware.

        5.9     Headings. The captions and headings used in this Agreement are
for convenience only and are not to be used in interpreting the rights and
obligations of the parties under this Agreement.

        5.10    Waiver. No delay or omission by any party to exercise any right
or power it has under this Agreement shall impair or be construed as a waiver of
such right or power. A waiver by any party of any breach or covenant shall not
be construed to be a waiver of any succeeding breach or any other covenant. All
waivers must be in writing signed by all parties.

        5.11    Advice of Counsel. The parties represent that they have relied
upon the legal advice of their own attorneys, who are attorneys of their own
choosing. The parties further represent that they have read the terms of this
Agreement, in their entirety, and that those terms are fully understood and
voluntarily accepted by each of the parties.

        5.12    Interpretation. No provision of this Agreement is to be
interpreted for or against any party because that party or its attorney drafted
the provision.

        5.13    Severability. If for any reason a competent authority finds any
provision of this Agreement, or portion thereof, to be unenforceable, that
provision or portion shall be enforced to the maximum extent permissible so as
to effect the intent of the parties, and the remainder of this Agreement shall
continue in full force and effect.

        5.14    Relationship. Nothing contained in this Agreement shall be
construed to make the parties partners, joint venturers, principals, agents or
employees of the other.

        5.15    Counterparts. This Agreement may be executed in any number of
counterparts, each of which will be deemed an original, but all of which taken
together shall constitute one single agreement among the parties.

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                        6

<PAGE>

        IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
sinned below by their respective duly authorized officers.

LEXICON GENETICS INCORPORATED              DELTAGEN, INC.

By:                                        By:
      ----------------------------                ----------------------------

Title:                                     Title:
      ----------------------------                ----------------------------

Date:                                      Date:
      ----------------------------                ----------------------------

GENPHARM INTERNATIONAL, INC.               THE UNIVERSITY OF UTAH
                                           RESEARCH FOUNDATION

By:                                        By:
      ----------------------------                ----------------------------

Title:                                     Title:
      ----------------------------                ----------------------------

Date:                                      Date:
      ----------------------------                ----------------------------

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                        7

<PAGE>

                                    EXHIBIT A

                          UNITED STATES DISTRICT COURT
                          FOR THE DISTRICT OF DELAWARE

LEXICON GENETICS, INCORPORATED, a          C.A. No. 00-516-JJF
Delaware Corporation, and GENPHARM
INTERNATIONAL, INCORPORATED, a California
Corporation

             Plaintiffs,
       v.

DELTAGEN, INC., a Delaware Corporation

             Defendant.

                     STIPULATION OF DISMISSAL WITH PREJUDICE

        Pursuant to Fed. R. Civ. P. 41(a)(1), the parties hereby stipulate to
the dismissal with prejudice of this action, including all claims and
counterclaims filed herein.

DATED: September ___, 2001        By:
                                     -------------------------------------------
                                     Richard Horwitz, Esq.
                                     James M Kron, Esq.
                                     POTTER ANDERSON & CORROON, LLP
                                     Hercules Plaza
                                     1313 N. Market Street
                                     Wilmington, DE 19899 0951

                                     David L. Bilsker, Esq.
                                     Buckmaster De Wolf, Esq.
                                     Mark A. Seka, Esq.
                                     HOWREY SIMON ARNOLD & WHITE LLP
                                     301 Ravenswood Avenue
                                     Menlo Park, CA 94025

                                     Counsel for Plaintiff Lexicon Genetics Inc.

STIPULATION OF DISMISSAL WITH PREJUDICE Civil Action No. 00 516 JIF

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

<PAGE>

DATED: September ___, 2001        By:
                                     -------------------------------------------
                                     Patrick Smink Rogowski, Esq.
                                     CONNOLLY BOVE LODGE & HUTZ, LLP
                                     1220 Market Street
                                     P.O. Box 2207
                                     Wilmington, DE 19899

                                     Kevin C. McCann, Esq.
                                     LASKY, HAAS & COHLER
                                     Two Transamerica Center
                                     505 Sansome Street
                                     San Francisco, CA 94111

                                     William Scofield, Esq.,
                                     LAHIVE & COCKFIELD, LLP
                                     28 State Street
                                     Boston, MA 02109 1784

                                     Counsel for Involuntary Plaintiff GenPharm
                                     International

DATED: September ___, 2001        By:
                                     -------------------------------------------
                                     Josy W. Ingersoll, Esq.
                                     John W. Shaw, Esq.
                                     YOUNG CONAWAY STARGATT & TAYLOR, LLP
                                     Rodney Square North, 11th Floor
                                     P.O. Box 391
                                     Wilmington, DE 19899 0391

                                     Gerald Sobel, Esq.
                                     Aaron Stiefel, Esq.
                                     Daniel DiNapoli, Esq.
                                     Todd Holmbo, Esq.
                                     KAYE, SCHOLER, FIERMAN, HAYS & HANDLER, LLP
                                     425 Park Avenue
                                     New York, NY 10022 3598

                                     Counsel for Defendant Deltagen Inc.

STIPULATION OF DISMISSAL WITH PREJUDICE Civil Action No. 00 516 JIF

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                       -2-

<PAGE>

                       IN THE UNITED STATES DISTRICT COURT

                     FOR THE NORTHERN DISTRICT OF CALIFORNIA

                                SAN JOSE DIVISION

LEXICON GENETICS INCORPORATED,             Case No. CV-00-21060 PVT ADR
a Delaware Corporation,

                                           STIPULATION OF DISMISSAL
           Plaintiff,                      WITH PREJUDICE
and

University of Utah Research Foundation

           (Nominal Plaintiff)

DELTAGEN, INC., a Delaware Corporation,
            Defendant.

        Pursuant to Fed. R. Civ. P. 41(a)(1), the parties hereby stipulate to
the dismissal with prejudice of this action, including all claims and
counterclaims filed herein.

DATED: September___, 2001         By:
                                     -------------------------------------------
                                     David L. Bilsker, Esq.
                                     Buckmaster De Wolf, Esq.
                                     Mark A. Seka, Esq.
                                     HOWREY SIMON ARNOLD & WHITE LLP
                                     301 Ravenswood Avenue
                                     Menlo Park, CA 94025

                                     Counsel for Plaintiff Lexicon Genetics Inc.

STIPULATION OF DISMISSAL WITH PREJUDICE

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

<PAGE>

DATED: September___, 2001         By:
                                     -------------------------------------------
                                     George A. Riley
                                     O'MELVENY & MYERS, LLP
                                     Embarcadero Center West
                                     275 Battery Street
                                     San Francisco, CA 94111 3305
                                     T: 415.984.8700
                                     F: 415.984.8701

                                     Counsel for Nominal Plaintiff University of
                                     Utah Research Foundation

DATED: September___, 2001         By:
                                     -------------------------------------------
                                     Stephen D. Leanos
                                     TOMLINSON ZISKO MOROSOLI &
                                       MASER, LLP
                                     200 Page Mill Road
                                     Palo Alto, CA 94306

                                     Gerald Sobel
                                     Aaron Stiefel
                                     Daniel DiNapoli
                                     Todd Holmbo
                                     KAYE SCHOLER LLP
                                     425 Park Avenue
                                     New York, NY 10022-3598

                                     Counsel for Defendant Deltagen Inc.

STIPULATION OF DISMISSAL WITH PREJUDICE

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

<PAGE>

                             CERTIFICATE OF SERVICE

        I hereby certify that copies of the foregoing STIPULATION OF DISMISSAL
WITH PREJUDICE was served by facsimile and regular United States mail, postage
prepaid, this ____th day of August, 2001 upon:

                                     Gerald Sobel
                                     Aaron Stiefel
                                     Daniel DiNapoli
                                     Todd Holmbo.
                                     KAYE SCHOLER LLP
                                     425 Park Avenue
                                     New York, NY 10022-3598
                                     T: 212.836.8000
                                     F: 212.836.7159

                                     James R. Busselle
                                     TOMLINSON ZISKO MOROSOLI &
                                      MASER, LLP
                                     200 Page Mill Road
                                     Palo Alto, CA 94306
                                     T: 650.325.8666
                                     F: 650.324.1808

                                     George A. Riley
                                     O'MELVENY & MYERS, LLP
                                     Embarcadero Center West
                                     275 Battery Street
                                     San Francisco, CA 94111-3305
                                     T: 415.984.8700
                                     F: 415.984.8701

                                     -------------------------------------------
                                                      Karen Leaver
CERTIFICATE OF SERVICE

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]